Enzolytics, Inc. (ENZC)

0.0053 +0.0004 (+7.29%) At close: 03:59PM EDT

Enzolytics, Inc.

2000 North Central Expressway
Plano, TX 75074
United States
972 292 9414
https://enzolytics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Harry H. Zhabilov Jr., BSc, McS Science	CSO & Chairman	N/A	N/A	1967
Steven Sharabura	Chief Executive Officer	N/A	N/A	N/A
Mr. Charles S. Cotropia	President & Director	N/A	N/A	N/A
Diana Zhabilov	Chief Financial Officer	N/A	N/A	N/A
Dr. Gaurav Chandra M.D.	COO & Director	N/A	N/A	N/A
Dr. Joseph P. Cotropia M.D.	Chief Medical Officer & Director	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Enzolytics Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics Inc. is based in Plano, Texas.

Corporate Governance

Enzolytics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.